Liquid Biopsy Market Size to grow by USD 3696.4 million between 2024-2028
According to a research report “ Liquid Biopsy Market” by Application (Cancer applications, Non-cancer applications) Technology (CTC and ctDNA, Exosome and RNA) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 3696.4 million, at a CAGR of almost 25.2% during the forecast period. In the global healthcare landscape, cancer continues to pose a significant challenge, with approximately 50% of new cases and 52% of related deaths affecting men. Among the various types of cancer, lung cancer holds the distinction of being the most prevalent, accounting for a substantial market share in the oncology sector. The uncontrolled cell division resulting from a combination of hereditary and environmental risk factors necessitates innovative diagnostic solutions. Enter Liquid Biopsy, an emerging technology in the diagnostic market, offering early detection, minimal invasiveness, and actionable insights for personalized treatment plans. This cutting-edge technology holds immense potential in addressing the diagnostic challenges associated with various types of cancers, including lung cancer, thereby contributing to improved patient outcomes and reduced morbidity.
Browse market data tables, figures, and in-depth TOC on “Liquid Biopsy Market” by Application (Cancer applications, Non-cancer applications) Technology (CTC and ctDNA, Exosome and RNA) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Application, the Cancer applications segment is projected to dominate the market size in 2024
The Liquid Biopsy Market represents a significant business opportunity in the healthcare sector, offering minimally invasive diagnostic solutions. This market's growth is driven by the increasing prevalence of cancer and other diseases, as well as advancements in technology enabling the detection of circulating biomarkers in bodily fluids. Companies investing in Liquid Biopsy stand to gain from this burgeoning industry, catering to the unmet medical need for early and accurate disease diagnosis.
By Technology, CTC and ctDNA segment is expected to hold the largest market size for the year 2024
The Liquid Biopsy Market represents a significant business opportunity in the healthcare sector, offering minimally invasive diagnostic solutions. This market's growth is driven by the increasing prevalence of cancer and other diseases, as well as advancements in technology enabling the detection of circulating biomarkers in bodily fluids. Companies investing in Liquid Biopsy stand to gain from this burgeoning industry, catering to the unmet medical need for early and accurate disease diagnosis.
North America is forecasted to hold the largest market size by region in 2024
The Liquid Biopsy Market represents a significant business opportunity in the healthcare sector, offering minimally invasive diagnostic solutions. This market's growth is driven by the increasing prevalence of cancer and other diseases, as well as advancements in technology enabling the detection of circulating biomarkers in bodily fluids. Companies investing in Liquid Biopsy stand to gain from this burgeoning industry, catering to the unmet medical need for early and accurate disease diagnosis.
The Liquid Biopsy Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The Liquid Biopsy Market encompasses innovative technologies and solutions from various industry leaders, including ScreenCell, Predicine, Personal Genome Diagnostics, ONCODE Scientific, NeoGenomics, Miltenyi Biotec, MDNA Life Sciences, Lucence, Grail, Naveris, Merck KgaA, Foundation Medicine, Helio Genomics, Sysmex Inostics, Singlera Genomics, DiaCarta, and Guardant Health. These companies are revolutionizing cancer diagnostics and treatment through the utilization of liquid biopsies, which offer several advantages over traditional methods. Liquid biopsies enable the detection of cancer biomarkers, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes, from a patient's blood or other bodily fluids. This non-invasive approach is particularly valuable for patients with advanced or metastatic cancers, as it allows for real-time monitoring of cancer progression and response to treatment. The market for liquid biopsy solutions is expected to grow significantly due to increasing cancer awareness initiatives, rising cancer deaths, and the need for more effective and personalized treatment options. According to SEER statistics, an estimated 1.9 million new cancer cases and 608,570 cancer deaths are projected to occur in the US alone in 2022. The injection pen market is also expected to benefit from the growing demand for liquid biopsy solutions, as these devices facilitate the easy and accurate collection and processing of patient samples. The National Institutes of Health (NIH) and other research organizations are investing heavily in the development of new biomarkers and technologies for liquid biopsy applications. These efforts are expected to lead to significant advancements in cancer diagnostics and treatment, ultimately improving the quality of life for cancer patients.
Market Research Overview
In the dynamic landscape of cancer diagnostics, the Liquid Biopsy Market has emerged as a promising sector, driven by advanced technologies such as Next-Generation Sequencing (NGS) and the discovery of novel cancer biomarkers. This market caters to both private and public organizations, including laboratories that are NABL-accredited and hospitals. The prevalence of cancer varies across developed markets and developing economies, necessitating cost-effective, minimally invasive procedures for patient stratification and monitoring. Liquid biopsy products, such as assay kits and LDT scenario, enable the analysis of tumor DNA from plasma, providing valuable insights into cancer signatures and tumor types, including sarcomas and gliomas. The market is witnessing significant funding and investments, with key players like Grail, Merck KgaA, and Foundation Medicine leading the way. The use of liquid biopsy in cancer diagnosis and treatment, including surgery and customized therapies, is transforming patient outcomes and quality of life. The market also includes emerging technologies like SEER statistics and data requirements for medical tourism and patient population analysis. Key areas of focus include the prevalence of cancer in various tumor types, such as cervical and breast cancer, and the development of cancer awareness initiatives to influence buying behavior in the injection pen market. The NIH and other research institutions continue to invest in biomarkers and NGS-panel tests to expand the scope of liquid biopsy applications.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
